From the 7 September 2023, UK scientists can apply for funding from the largest R&D collaboration programme globally, thus accelerating therapeutic advancement.
List view / Grid view
Association of the British Pharmaceutical Industry (ABPI)
Funding to support the UK's life sciences manufacturing, skills and infrastructure has been announced as part of a £650m growth package.
A new approach to the cost-comparison fast-track appraisal process is being piloted this summer for the review of low-risk appraisals.
In this final article on the TRIPS waiver for COVID-19 vaccines, medicines, diagnostics and technologies, EPR’s Hannah Balfour considers whether it is the correct strategy to overcome COVID-19 treatment inequalities and explores other options.
The ABPI’s 2021 pharmaceutical industry Code of Practice aims to increase transparency, encourage collaboration and improve patient care.
A new report has shown that the pharmaceutical industry in Scotland employs nine percent more people now than in 2018.
The ABPI has commented on the new Spending Review and outlined ways the UK government can help the life sciences sector.
The ABPI has found that the UK is leading the rest of Europe in early-stage clinical trials and makes suggestions on how the country can maintain this position.
1 October 2020 | By
UK politicians were warned that without a post-Brexit deal on medicines, short-term supply delays could be damaging to both public health and the economy.
The ABPI and EFPIA have both emphasised the need for trade talks to mitigate medicine supply chain disruptions following Brexit.
The ABPI has said that the new UK-Japan free trade agreement will benefit the pharma industry, providing continuity for life science businesses.
The ABPI has responded to new guidance, intended to prepare pharma companies for the end of the Brexit transition period, from the MHRA.
The ABPI's Dr Richard Torbett, speaking to the International Trade Committee, said the COVID-19 pandemic highlights the need for a globalised drug supply chain.
The UK government has pledged funding of £22 billion per year into R&D by 2025 in its Budget, just days after a further £46 million was invested into coronavirus research.
The ABPI has outlined how the new immigration system in the UK will affect life science workers and businesses, emphasising the need for regular reviews to remain competitive.